Cancer Center Launches Personalized Medicine Institute

March 2012, Vol 3, No 2 - Value Propositions


Moffitt Cancer Center in Tampa, FL, has announced it is launching its Personalized Medicine Institute to advance the fight against cancer, and implementing the promise of personalized cancer care medicine by focusing on innovative biotechnology with its biotechnology subsidiary M2Gen. Moffitt’s Board Chairman Robert Rothman said that “the time is now, because cancer research and treatment is at an inflection point that requires the right mix of visionary leadership and collaboration to realize the promise of personalized cancer care for patients everywhere.”

Moffitt’s Chief Executive Officer William S. Dalton, PhD, MD, will focus on the establishment of the institute, highlighting the value of such an approach. “Moffitt’s investment in Total Cancer Care has positioned us to realize the dream of cancer therapy based on the right treatment, for the right patient, at the right time. Our unique clinical trial matching process has been recognized by an issued patent. M2Gen is partnering with Merck and other pharmaceutical and biotechnology companies to launch the first clinical trials in which patients have been recruited using the world’s largest cancer-focused biorepository,” Dr Dalton said. Moffitt Cancer Center press release; February 22, 2012.